Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

Similar articles for PubMed (Select 21968355)

1.

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.

Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, Arrieta A, Graham ML, Bradfield SM, Baruch A, Liu P.

Antimicrob Agents Chemother. 2011 Dec;55(12):5770-9. doi: 10.1128/AAC.00531-11. Epub 2011 Oct 3.

2.

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.

Driscoll TA, Frangoul H, Nemecek ER, Murphey DK, Yu LC, Blumer J, Krance RA, Baruch A, Liu P.

Antimicrob Agents Chemother. 2011 Dec;55(12):5780-9. doi: 10.1128/AAC.05010-11. Epub 2011 Sep 12.

3.

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, Jafri H, Arrieta AC, Klein NJ, Lutsar I.

Antimicrob Agents Chemother. 2010 Oct;54(10):4116-23. doi: 10.1128/AAC.00896-10. Epub 2010 Jul 26.

4.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N.

Antimicrob Agents Chemother. 2004 Jun;48(6):2166-72.

5.

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D.

Antimicrob Agents Chemother. 2002 Aug;46(8):2546-53.

6.

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, Mauz-Körholz C, Preiss R.

Antimicrob Agents Chemother. 2010 Aug;54(8):3225-32. doi: 10.1128/AAC.01731-09. Epub 2010 Jun 14.

7.

Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.

Friberg LE, Ravva P, Karlsson MO, Liu P.

Antimicrob Agents Chemother. 2012 Jun;56(6):3032-42. doi: 10.1128/AAC.05761-11. Epub 2012 Mar 19.

8.

Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.

Andrews E, Damle BD, Fang A, Foster G, Crownover P, LaBadie R, Glue P.

Br J Clin Pharmacol. 2008 Apr;65(4):531-9. doi: 10.1111/j.1365-2125.2007.03084.x. Epub 2008 Feb 21.

9.

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.

Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD.

Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:10-6.

10.

Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.

Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A.

J Clin Pharmacol. 2002 Apr;42(4):395-402.

PMID:
11936564
11.

The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.

Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D.

Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:2-9.

12.

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.

Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, Mikus G.

Br J Clin Pharmacol. 2009 Dec;68(6):906-15. doi: 10.1111/j.1365-2125.2009.03534.x.

13.

Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, Russomanno JH, Shore E, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2009 Dec;53(12):5102-7. doi: 10.1128/AAC.01042-09. Epub 2009 Sep 21.

14.

Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.

Soler-Palacín P, Frick MA, Martín-Nalda A, Lanaspa M, Pou L, Roselló E, de Heredia CD, Figueras C.

J Antimicrob Chemother. 2012 Mar;67(3):700-6. doi: 10.1093/jac/dkr517. Epub 2011 Dec 21.

15.

Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Berge M, Guillemain R, Trégouet DA, Amrein C, Boussaud V, Chevalier P, Lillo-Lelouet A, Le Beller C, Laurent-Puig P, Beaune PH, Billaud EM, Loriot MA.

Eur J Clin Pharmacol. 2011 Mar;67(3):253-60. doi: 10.1007/s00228-010-0914-2. Epub 2010 Oct 31.

PMID:
21038076
16.

Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.

Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH.

J Antimicrob Chemother. 2012 Nov;67(11):2717-24. doi: 10.1093/jac/dks258. Epub 2012 Jul 13.

17.

Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.

Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O.

Clin Infect Dis. 2012 Aug;55(3):381-90. doi: 10.1093/cid/cis437. Epub 2012 May 18.

18.

Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.

Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D.

Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:17-23.

19.

Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.

Mori M, Kobayashi R, Kato K, Maeda N, Fukushima K, Goto H, Inoue M, Muto C, Okayama A, Watanabe K, Liu P.

Antimicrob Agents Chemother. 2015 Feb;59(2):1004-13. doi: 10.1128/AAC.04093-14. Epub 2014 Dec 1.

20.

Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.

Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, Haefeli WE.

Clin Pharmacol Ther. 2006 Aug;80(2):126-35. Epub 2006 Jul 3.

PMID:
16890574
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk